Erectile dysfunction (ED) remains one of the most prevalent and emotionally charged conditions in men’s health. Although clinicians traditionally focus on pharmacological efficacy and safety, the patient’s own preference — his perceptions, expectations, and priorities — often determines whether a treatment will be used consistently enough to succeed. Over the past 25 years, researchers attempted to capture these preferences through randomized controlled trials (RCTs), offering a rare glimpse into how men navigate between pills, injections, devices, and the promise of spontaneity.
This article distills the essence of those findings into a clear, engaging, and medically rigorous narrative. Drawing directly from the systematic review of RCTs evaluating treatment preferences in ED patients, the discussion below not only synthesizes evidence but also interprets it in the context of modern clinical practice. Because when it comes to sexual health, effectiveness matters — but so does everything around it.
How Erectile Dysfunction Treatments Compete for Patient Preference
The modern therapeutic landscape for ED is broad, yet oral phosphodiesterase type-5 inhibitors (PDE5Is) — sildenafil, tadalafil, vardenafil — dominate global prescribing trends. Their convenience, rapid onset, and predictable effects made them the de facto first-line therapies. But preference is a more nuanced phenomenon. It blends pharmacokinetics with a man’s lifestyle, his expectations about sexual spontaneity, and sometimes even the subtle psychology of not wanting to pull out a syringe during foreplay.
Across 18 eligible studies and more than 6,800 randomized participants, several consistent patterns emerged. Interestingly, none of the trials used a validated tool for assessing treatment preference, relying instead on simple direct-choice questions — an elegant, if imperfect, reflection of “Which did you actually like better?” Despite methodological heterogeneity and high risk of bias across studies, the evidence paints a remarkably stable picture of how men choose between available options.
Patients tended to favor treatments that were easy to administer, produced reliable erections, allowed flexibility in timing, and minimized awkward procedural steps. Sildenafil, as the first PDE5I approved in 1998, quickly became a reference standard — but tadalafil, with its longer duration of action, gradually became the preferred option in head-to-head trials. Even within the same drug, men developed preferences for dosing schedules and formulations, highlighting the importance of personalization in ED therapy.
Why Tadalafil Often Wins the Popularity Contest
Among all comparisons, the preference for tadalafil over sildenafil appeared the most consistent. Across multiple RCTs, 66–73% of men favored tadalafil, and roughly one-third expressed a strong preference. Surprisingly, this preference persisted regardless of ED etiology, age, disease severity, comorbidities, or treatment sequence. In other words, tadalafil’s popularity was democratic.
The reason most often cited? A detail that may seem modest from a pharmacological perspective but is monumental in lived experience: the ability to achieve an erection long after taking the drug. Men valued the freedom to “not race against the pill.” The window of opportunity — up to 36 hours — allowed sex to unfold naturally, instead of becoming an item on a schedule. This flexibility translated into reduced performance pressure, higher confidence, and a more intuitive sexual rhythm.
Some participants also appreciated tadalafil’s consistency, reporting that erections felt more predictable and reliable. Others noted the firmness of erection as a deciding factor. Interestingly, pharmacokinetic constraints — such as sildenafil’s sensitivity to food interactions — did not go unnoticed. For men who prefer spontaneous intimacy after a hearty dinner, tadalafil felt refreshingly permissive.
A curious but clinically relevant detail emerged: while tadalafil 20 mg as needed was preferred by 57–59% of patients over the 3-times-per-week regimen, the scheduled regimen still retained appeal for men uncomfortable with planning intercourse or those perceiving continuous therapy as a form of “sexual readiness insurance.”
Throughout the evidence, tadalafil’s advantage rested not merely on efficacy but on the psychological comfort of liberated timing — a reminder that ED treatment succeeds as much in the mind as in the corpus cavernosum.
Sildenafil: Still Respected, Still Effective, Still Second Place
Despite tadalafil’s rise, sildenafil retained a loyal user base. In trials comparing sildenafil with placebo, 78–100% of men preferred sildenafil — a reassuring confirmation of therapeutic benefit. When compared with intracavernosal injections (ICI), sildenafil again emerged as the favored option for approximately 70% of men, largely due to its less invasive administration.
However, when sildenafil faced tadalafil, the balance tipped. Only 27–34% chose sildenafil, citing firmness and rapid onset as key advantages. It’s worth noting that a significant proportion of men appreciated sildenafil’s relatively “short window,” interpreting it as a way to confine side effects to a smaller timeframe — an interesting counter-perspective in preference psychology.
When researchers compared sildenafil tablets with orodispersible strips, no meaningful difference emerged (53% vs. 47%). Convenience, it seems, is appreciated but not transformative.
In clinical practice, sildenafil remains indispensable. It is highly effective, widely available, often more affordable, and possibly preferable for men desiring a tighter temporal relationship between drug intake and sexual activity. However, the evidence suggests that when patients are given a real choice in blinded or pseudo-blinded conditions, tadalafil’s longer duration generally wins the emotional argument.
The Role of Injections, Creams, and Devices: Necessary Options, Rare Favorites
Although PDE5 inhibitors dominate, second-line and third-line treatments still play crucial roles — especially for patients who fail oral therapy or have contraindications. These methods include intracavernosal injections (ICI), intraurethral suppositories, topical alprostadil, vacuum erection devices, and penile implants. Preference studies comparing these alternatives revealed predictable but clinically important trends.
Men overwhelmingly preferred sildenafil or ICI over vacuum erection devices — in fact, 100% of participants in one RCT rejected the vacuum device when given alternatives. This finding, while unsurprising, reinforces an important clinical truth: although vacuum devices are effective and safe, their mechanical nature and required preparation steps make them less appealing to most men.
Between ICI and intraurethral therapy (MUSE), intracavernosal alprostadil emerged as the preferred option for the majority of men (69%). Participants valued the reliability and superior erectile quality, despite acknowledging injections as less pleasant. Ironically, even the discomfort of a needle did not overcome the stronger desire for an erection that works. Yet it is equally important to acknowledge why many men still avoid injections in practice: anxiety, fear of pain, and lack of manual dexterity — factors often underrepresented in RCTs.
For topical alprostadil cream, application within the urethral meatus was preferred over application on the glans tip, primarily due to lower perceived risk of drug dispersion. This small but meaningful distinction again underscores how micro-details shape patient satisfaction.
Ultimately, non-oral therapies remain essential but are rarely first choices when oral agents are effective. The preference hierarchy is clear: pills first, injections next, devices last — unless specific clinical circumstances dictate otherwise.
What Truly Drives Treatment Preference? A Three-Dimensional Model
By analyzing patterns across trials, researchers identified three broad categories influencing patient preference: treatment factors, patient factors, and partner factors. Each category interacts dynamically, and the importance of each factor varies between individuals and couples.
Treatment factors include:
- the ability to achieve a firm erection
- reliability and consistency across attempts
- onset and duration of action
- naturalness of the erection
- route of administration
- adverse effect profile
Patient factors incorporate age, dexterity, psychological readiness, sexual frequency, prior experiences, self-confidence, and expectations about spontaneity. Partner factors, though under-studied, unquestionably influence decision-making — as sexual activity is inherently relational.
Interestingly, several large trials found no significant associations between preference and variables such as age, ED etiology, duration of ED, sequence of treatment exposure, or comorbidities. Instead, preference correlated more closely with perceived improvements in functional domains measured by instruments such as the International Index of Erectile Function (IIEF), Sexual Encounter Profile (SEP), and Psychological and Interpersonal Relationship Scales (PAIRS). Even subtle differences in side-effect perception influenced choices more strongly than objective measures like lipid profiles or glycemic control.
A clear pattern emerged: men choose the treatment that helps them feel more confident, less pressured, and more autonomous. Pharmacology alone cannot explain this — it is a confluence of physiology and emotion.
Limitations in the Evidence — And Why They Matter
The systematic review underscores important methodological limitations in preference research. All RCTs carried a high risk of bias, largely due to challenges inherent in ED therapy comparisons. For instance, blinding becomes nearly impossible when drugs differ in timing, onset, and food interactions. Many trials were industry-sponsored, doses varied widely, and crossover designs complicated statistical interpretations.
Moreover, although nearly 7,000 men participated across studies, many RCTs focused on niche populations — such as spinal cord injury patients or men with cardiovascular risk factors — limiting generalizability. The reasons behind patient preferences were frequently underreported, and validated instruments for measuring preference simply did not exist.
Despite these limitations, the convergence of findings across 25 years of research suggests that the core insights are robust: men gravitate toward treatments that align with their desire for spontaneity, comfort, and predictability.
Conclusion
Across decades of randomized trials, the preferences of men with erectile dysfunction reveal a coherent, clinically meaningful narrative. Oral PDE5 inhibitors remain the cornerstone of ED therapy, with tadalafil consistently preferred over sildenafil, largely due to its extended duration of action and greater perceived spontaneity. Sildenafil maintains strong appeal and remains indispensable, especially for men seeking rapid onset and short-lasting effects. Invasive therapies, while effective, occupy supportive roles for patients who fail or cannot tolerate oral treatments.
Ultimately, the best ED therapy is not merely the one with the strongest clinical data but the one a man is willing and motivated to use. Understanding his motivations, fears, lifestyle, and expectations transforms treatment from a prescription into a partnership.
FAQ
1. Why do most men prefer tadalafil over sildenafil?
Because tadalafil offers a much longer window of effectiveness — up to 36 hours — men feel less pressured to time sexual activity around medication. This “weekend effect” allows more spontaneity and reduces performance anxiety.
2. Are injections or vacuum devices good options if pills don’t work?
Yes. Intracavernosal injections can be extremely effective and are preferred over vacuum devices, although they require comfort with self-injection. Vacuum devices work reliably but are often rejected due to mechanical complexity and reduced naturalness of intercourse.
3. Do side effects influence treatment preference?
Absolutely. Even mild adverse effects — headaches, flushing, nasal congestion — can affect a patient’s willingness to continue therapy. Interestingly, subjective perception of side effects can influence preference more than their clinical severity.
